

María Asunción García-González

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6657255/publications.pdf>

Version: 2024-02-01

60
papers

2,055
citations

236925

25
h-index

233421

45
g-index

61
all docs

61
docs citations

61
times ranked

2301
citing authors

#	ARTICLE	IF	CITATIONS
1	Familial Colorectal Cancer and Genetic Susceptibility: Colorectal Risk Variants in First-Degree Relatives of Patients With Colorectal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00301.	2.5	3
2	Predictive Value of Genetic Risk Scores in the Development of Colorectal Adenomas. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	1
3	Quantitative analysis of p16 methylation in Barrett's carcinogenesis. <i>Annals of Diagnostic Pathology</i> , 2020, 47, 151554.	1.3	1
4	Genetic susceptibility in the development of colorectal adenomas according to family history of colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 489-502.	5.1	10
5	Adding genetic scores to risk models in colorectal cancer. <i>Oncotarget</i> , 2019, 10, 4803-4804.	1.8	2
6	Evidence for <i>PTGER4</i> , <i>PSCA</i> and <i>MBOAT7</i> as risk genes for gastric cancer on the genome and transcriptome level. <i>Cancer Medicine</i> , 2018, 7, 5057-5065.	2.8	22
7	CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells. <i>Frontiers in Pharmacology</i> , 2017, 8, 321.	3.5	8
8	Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype. <i>Oncotarget</i> , 2017, 8, 35848-35862.	1.8	14
9	Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. <i>Frontiers in Pharmacology</i> , 2016, 7, 452.	3.5	20
10	Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2896-2907.	2.3	7
11	Association of <i>PSCA</i> rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease. <i>International Journal of Cancer</i> , 2015, 137, 1362-1373.	5.1	39
12	Deconvolution Analysis for Classifying Gastric Adenocarcinoma Patients Based on Differential Scanning Calorimetry Serum Thermograms. <i>Scientific Reports</i> , 2015, 5, 7988.	3.3	30
13	<i>In Vitro</i> Vitamin K ₃ Effect on Conjunctival Fibroblast Migration and Proliferation. <i>Scientific World Journal</i> , The, 2014, 2014, 1-5.	2.1	2
14	Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. <i>Oncology Reports</i> , 2014, 31, 2785-2791.	2.6	4
15	Genetic susceptibility and gastric cancer risk: The importance of meta-analyses as a statistical tool. <i>Gastroenterology y Hepatología</i> , 2014, 37, 421-426.	0.5	10
16	Molecular Pathogenesis of Gastric Cancer. <i>Helicobacter</i> , 2013, 18, 28-33.	3.5	57
17	Mo1122 Relevance of <i>PSCA</i> Rs2294008 Gene Polymorphism on Gastric Cancer Risk and Prognosis. <i>Gastroenterology</i> , 2013, 144, S-583-S-584.	1.3	1
18	Characterization of the Prostaglandin E2 Pathway in a Rat Model of Esophageal Adenocarcinoma. <i>Current Cancer Drug Targets</i> , 2012, 12, 132-143.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Su1854 Association of TP53 Arg72pro Variants With Gastric Cancer Risk in Helicobacter pylori Infected Subjects: A Nation-Wide Case-Control Study in Spain. <i>Gastroenterology</i> , 2012, 142, S-519.	1.3	1
20	Relevance of GSTM1, GSTT1, and GSTP1 gene polymorphisms to gastric cancer susceptibility and phenotype. <i>Mutagenesis</i> , 2012, 27, 771-777.	2.6	53
21	Prognostic Role of Host Cyclooxygenase and Cytokine Genotypes in a Caucasian Cohort of Patients with Gastric Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e46179.	2.5	9
22	Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. <i>World Journal of Gastroenterology</i> , 2012, 18, 4866.	3.3	8
23	Relevance of DNA Repair Gene Polymorphisms on Gastric Cancer Susceptibility and Phenotype. <i>Gastroenterology</i> , 2011, 140, S-354.	1.3	1
24	Association of IL10 promoter polymorphisms with idiopathic achalasia. <i>Human Immunology</i> , 2011, 72, 749-752.	2.4	26
25	Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 440-451.	3.7	32
26	Relevance of IL-1 and TNF gene polymorphisms on interleukin-1 β and tumor necrosis factor- α gastric mucosal production. <i>Human Immunology</i> , 2009, 70, 935-945.	2.4	24
27	Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: Results 3 years after gastroenteritis. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1173-1185.	1.5	46
28	A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin. <i>Clinical Therapeutics</i> , 2008, 30, 121-130.	2.5	19
29	Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?. <i>Current Pharmaceutical Design</i> , 2007, 13, 2261-2273.	1.9	28
30	Gastric Cancer Susceptibility Is Not Linked to Pro-and Anti-Inflammatory Cytokine Gene Polymorphisms in Whites: A Nationwide Multicenter Study in Spain. <i>American Journal of Gastroenterology</i> , 2007, 102, 1878-1892.	0.4	117
31	CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate. <i>BMC Gastroenterology</i> , 2006, 6, 7.	2.0	24
32	TGFB1 gene polymorphisms: their relevance in the susceptibility to Helicobacter pylori-related diseases. <i>Genes and Immunity</i> , 2006, 7, 640-646.	4.1	20
33	Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. <i>Prostaglandins and Other Lipid Mediators</i> , 2006, 81, 150-161.	1.9	26
34	Association Between Achalasia and Nitric Oxide Synthase Gene Polymorphisms. <i>American Journal of Gastroenterology</i> , 2006, 101, 1979-1984.	0.4	34
35	No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. <i>International Journal of Immunogenetics</i> , 2005, 32, 299-306.	1.8	23
36	Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor β 1 (TGFB1) gene polymorphisms. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 616-619.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Lack of association of IL-12 p40 gene polymorphism with peptic ulcer disease. <i>Human Immunology</i> , 2005, 66, 72-76.	2.4	14
38	Gender-Related Association Between the TGFBI+869 Polymorphism and Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 536-542.	1.2	4
39	Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. <i>Clinical and Experimental Immunology</i> , 2003, 134, 525-531.	2.6	48
40	Oxidative stress-related gene polymorphisms and susceptibility to Barrett's esophagus. <i>Gastroenterology</i> , 2003, 124, A633.	1.3	0
41	Lack of association of IL-1B and TGFBI gene polymorphisms with Barrett's esophagus. <i>Gastroenterology</i> , 2003, 124, A640-A641.	1.3	0
42	Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. <i>British Journal of Rheumatology</i> , 2002, 41, 1419-1423.	2.3	84
43	Genetic markers in clinically well defined patients with ulcerative colitis (UC). <i>Clinical and Experimental Immunology</i> , 2001, 115, 294-300.	2.6	112
44	Association of interleukin-1 gene family polymorphisms with duodenal ulcer disease. <i>Gastroenterology</i> , 2001, 120, A67-A68.	1.3	0
45	Polymorphisms of the Interleukin-1 Gene Family, Oral Microbial Pathogens, and Smoking in Adult Periodontitis. <i>Journal of Dental Research</i> , 2001, 80, 1695-1699.	5.2	105
46	The polymorphic IL-1B and IL-1RN genes in the aetiopathogenesis of peptic ulcer. <i>Clinical and Experimental Immunology</i> , 2001, 125, 368-375.	2.6	67
47	TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. <i>Genes and Immunity</i> , 2001, 2, 415-421.	4.1	61
48	Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. <i>Gut</i> , 2001, 49, 644-649.	12.1	60
49	TGFBI gene polymorphisms and inflammatory bowel disease. <i>Immunogenetics</i> , 2000, 51, 869-872.	2.4	20
50	Platelet-Derived Growth Factor and Epidermal Growth Factor Play a Major Role in Human Colonic Fibroblast Repair Activities. <i>European Surgical Research</i> , 2000, 32, 191-196.	1.3	17
51	Allelic variants of the thiopurine s-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. <i>American Journal of Gastroenterology</i> , 2000, 95, 2313-2317.	0.4	39
52	A New Model for the Induction of Tumours in the Forestomach of Rats by N-Methyl-N-Nitrosourea. <i>European Surgical Research</i> , 2000, 32, 315-321.	1.3	2
53	Association of interleukin-1 and interleukin-1 receptor antagonist genes with disease severity in MS. <i>Neurology</i> , 1999, 52, 595-595.	1.1	125
54	IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. <i>Immunogenetics</i> , 1999, 49, 527-531.	2.4	132

#	ARTICLE	IF	CITATIONS
55	Significant Differences in the Interleukin-1 γ and Interleukin-1 Receptor Antagonist Gene Polymorphisms in a Hungarian Population with Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 175-179.	1.5	51
56	In vitro wound repair by human gastric fibroblasts: implications for ulcer healing. <i>Digestive Diseases and Sciences</i> , 1998, 43, 1230-1240.	2.3	11
57	HLA-DRB1 * 03 , but not the TNFA -308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. <i>Immunogenetics</i> , 1998, 47, 451-455.	2.4	65
58	Collagen Secretion by Human Gastric and Skin Fibroblasts: Implications for Ulcer Healing. <i>European Surgical Research</i> , 1998, 30, 48-54.	1.3	7
59	TNF- β promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. <i>Journal of Neuroimmunology</i> , 1997, 72, 149-153.	2.3	214
60	Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. <i>Lancet</i> , The, 1995, 346, 979-980.	13.7	69